References
- Llach, F.; Bover, J. Renal osteodystrophies. In The Kidney. Brenner, B M., Ed.;W.B. Saunders Company: Philadelphia, 2000; Vol. 2, 2103–2186.
- Hamdy, N A. The spectrum of renal bone disease.Nephrol. Dial. Transplant. 1995, 10, (Suppl. 4) 14–18; discussion 37–43. [PUBMED], [INFOTRIEVE], [CSA]
- Goodman, W G.; Ramirez, J A.; Belin, T R.; , et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.Kidney Int. 1994, 46, 1160–1166. [PUBMED], [INFOTRIEVE], [CSA]
- Simonet, W S.; Lacey, D L.; Dunstan, C R.; , et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.Cell 1997, 89, 309–319., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lacey, D L.; Timms, E.; Tan, H.-L.; , et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation.Cell 1998, 93, 165–176. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bucay, N.; Sarosi, I.; Dunstan, C R.; , et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.Genes Dev. 1998, 12, 1260–1268. [PUBMED], [INFOTRIEVE], [CSA]
- Khosla, S. The OPG/RANKL/RANK system.Endocrinology 2001, 142, 5050–5055. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Haas, M.; Leko-Mohr, Z.; Roschger, P.; , et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients.Am. J. Kidney Dis. 2002, 39, (3) 580–586. [PUBMED], [INFOTRIEVE], [CSA]
- Coen, G.; Ballanti, P.; Balducci, A.; , et al. Serum osteoprotegerin and renal osteodystrophy.Nephrol. Dial. Transplant. 2002, 1782, 233–238. [CSA], [CROSSREF]
- Kazama, J J.; Shigematsu, T.; Yano, K.; , et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure.Am. J. Kidney Dis. 2002, 39, (3) 525–532. [PUBMED], [INFOTRIEVE], [CSA]
- Avbersek-Luznik, I.; Malesic, I.; Rus, I.; Marc, J. Increased levels of osteoprotegerin in hemodialysis patients.Clin. Chem. Lab. Med. 2002, 40, (10) 1019–1023. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wuster, C.; Heilmann, P.; Pereira-Lima, J.; Schlegel, J.; Anstatt, K.; Soballa, T. Quantitative ultrasonometry (QUS) for the evaluation of osteoporosis risk: reference data for various measurement sites, limitations and application possibilities.Exp. Clin. Endocrinol. Diabetes 1998, 106, 277–288. [PUBMED], [INFOTRIEVE], [CSA]
- Joly, J.; Westhovens, R.; Borghs, H.; , et al. Reference curve and diagnostic sensitivity for a new ultrasound device for the phalanges, the DBMsonic 1200, in Belgian women.Osteoporos. Int. 1999, 9, 284–289. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Njeh, C F.; Richards, A.; Boivin, C M.; Hans, D.; Fuerst, T.; Genant, H K. Factors influencing the speed of sound through the proximal phalanges.J. Clin. Densitom. 1999, 2, 241–249. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wüster, C.; Albanese, C.; De Aloysio, D.; , et al. Phalangeal osteosonogrammetry study: age-related changes, diagnostic sensitivity, and discrimination power.J. Bone Miner. Res. 2000, 15, 1603–1614. [CSA]
- Linee Guida Osteodistrofia Renale. SIN.G. Ital. Nefrol. 2003, 20, s83–s95. [CSA]
- Buemi, M.; Floccari, F.; Crisafulli, A.; , et al. Osteoprotegerin, IL6, IL1, TNF-α and TGF-β concentrations during a hemodialytic session.J. Nephrol 2005 18:148–153. [PUBMED], [INFOTRIEVE], [CSA]
- Yano, K.; Tsuda, E.; Washida, N.; , et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.J. Bone Miner. Res. 1999, 14, 518–527. [PUBMED], [INFOTRIEVE], [CSA]
- Fraher, L J.; Watson, P H.; Kisiel, M.; Natale, B W.; Hodsman, A B. Measurement of circulating osteoprotegerin (OPG) in human sera: inhibition of circulating OPG in osteoporotic patients treated with hPTH (1–34).J. Bone Miner. Res. 2000, 15, S441. [CSA]
- Jehle, P M.; Ostertag, A.; Schulten, K.; , et al. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.Kidney Int. 2000, 57, 423–436. [PUBMED], [INFOTRIEVE], [CSA]
- Rubin, J.; Ackert-Bickenell, C L.; Zhu, L.; , et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-KappaB ligand in vitro and OPG in vivo.J. Clin. Endocrinol. Metab. 2002, 87, (9) 4273–4279. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hofbauer, L C.; Dunstan, C R.; Spelsberg, T C.; Riggs, B L.; Khosla, S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines.Biochem. Biophys. Res. Commun. 1998, 250, 776–781. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Horwood, N J.; Elliot, J.; Martin, T J.; Gillespie, M T. Osteotropic agents regulate the expression of osteoclast differentation factor and osteoprotegerin in osteoblastic stromal cells.Endocrinology 1998, 139, 4743–4746. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Murakami, T.; Yamomoto, M.; Ono, K. Transforming growth factor-B1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells.Biochem. Biophys. Res. Commun. 1998, 252, 747–752. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pecovnik Balon, B.; Bren, A. Bone histomorphometry is still the golden standard for diagnosing renal osteodystrophy.Clin. Nephrol. 2000, 54, 463–469. [PUBMED], [INFOTRIEVE], [CSA]
- De Vernejoul, M C.; Kuntz, D.; Miravet, L.; Gueris, J.; Bielakoff, J.; Ryckewaert, A. Bone histomorphometry in hemodialyzed patients.Metab. Bone Dis. Relat. Res. 1981, 3, 175–179. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Montagnani, A.; Gonnelli, S.; Cepollaro, C.; , et al. Quantitative ultrasound in the assessment of skeletal status in uremic patients.J. Clin. Densitom. 1999, 2, (4) 389–395. [PUBMED], [INFOTRIEVE], [CSA]
- Amling, M.; Grote, H J.; Vogel, M.; Hahn, M.; Delling, G. Three-dimensional analysis of the spine in autopsy cases with renal osteodystrophy.Kidney Int. 1994, 46, 733–743. [PUBMED], [INFOTRIEVE], [CSA]
- Luisetto, G.; Camozzi, V.; De Terlizzi, F. Use of quantitative ultrasonography in differentiating osteomalacia from osteoporosis: preliminary study.J. Ultrasound Med. 2000, 19, (4) 251–256. [PUBMED], [INFOTRIEVE], [CSA]
- Montagnani, A.; Gonnelli, S.; Cepollaro, C.; , et al. Graphic trace analysis of ultrasound at the phalanxes may differentiate between subjects with primary hyperparathyroidism and with osteoporosis: a pilot study.Osteoporos. Int. 2002, 13, (3) 222–227. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jamal, S A.; Chase, C.; Goh, Y I.; Richardson, R.; Hawker, G A. Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures.Am. J. Kidney Dis. 2002, 39, (4) 843–849. [PUBMED], [INFOTRIEVE], [CSA]
- Khosla, S. Minireview: the OPG/RANKL/RANK system.Endocrinology 2001, 142, 5050–5055. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]